During the last session, Alaunos Therapeutics Inc. (NASDAQ:TCRT)’s traded shares were 2.66 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stock’s price was $0.88, reflecting an intraday gain of 7.26% or $0.06. The 52-week high for the TCRT share is $2.94, that puts it down -234.09 from that peak though still a striking 53.41% gain since the share price plummeted to a 52-week low of $0.41. The company’s market capitalization is $185.67M, and the average trade volume was 2.91 million shares over the past three months.
Alaunos Therapeutics Inc. (TCRT) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.30. TCRT has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.07.
Alaunos Therapeutics Inc. (NASDAQ:TCRT) trade information
Alaunos Therapeutics Inc. (TCRT) registered a 7.26% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.26% in intraday trading to $0.88 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 3.22%, and it has moved by 70.01% in 30 days. Based on these gigs, the overall price performance for the year is -67.34%.
The consensus price target of analysts on Wall Street is $4.30, which implies an increase of 79.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.50 and $7.50 respectively. As a result, TCRT is trading at a discount of -752.27% off the target high and -70.45% off the low.
Alaunos Therapeutics Inc. (TCRT) estimates and forecasts
Statistics show that Alaunos Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Alaunos Therapeutics Inc. (TCRT) shares have gone down -33.44% during the last six months, with a year-to-date growth rate more than the industry average at 13.51% against 11.30. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 30.00% this quarter and then jump 36.40% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.60%. While earnings are projected to return 3.70% in 2022.
Alaunos Therapeutics Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Alaunos Therapeutics Inc. (NASDAQ:TCRT)’s Major holders
Alaunos Therapeutics Inc. insiders own 10.40% of total outstanding shares while institutional holders control 58.25%, with the float percentage being 65.00%. Blackrock Inc. is the largest shareholder of the company, while 212 institutions own stock in it. As of Dec 30, 2021, the company held over 16.76 million shares (or 7.76% of all shares), a total value of $18.27 million in shares.
The next largest institutional holding, with 16.7 million shares, is of Blackrock Inc.’s that is approximately 7.74% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $10.9 million.
Also, the Mutual Funds coming in first place with the largest holdings of Alaunos Therapeutics Inc. (TCRT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 9.55 million shares. This amounts to just over 4.42 percent of the company’s overall shares, with a $10.31 million market value. The same data shows that the other fund manager holds slightly less at 5.82 million, or about 2.69% of the stock, which is worth about $6.34 million.